Kidney Res Clin Pract > Volume 44(1); 2025 > Article |
|
The members of the World Kidney Day Joint Steering Committee: Alessandro Balducci, Vassilios Liakopoulos, Li-Li Hsiao, Ricardo Correa-Rotter, Ifeoma Ulasi, Latha A. Kumaraswami, Siu-Fai Lui, Dina Abdellatif, and Agnès Haris.
Conflicts of interest
Valerie A. Luyckx is chair of the Advocacy Working Group, International Society of Nephrology, with no financial disclosures. Katherine R. Tuttle has received research grants from the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities, director’s office), the U.S. Centers for Disease Control and Prevention, and Travere Therapeutics; and consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. She is chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology. Ricardo Correa-Rotter is a member of the Steering Committee of World Kidney Day, a member of the Diabetes Committee of the Latin-American Society of Nephrology and Hypertension (SLANH), and a member of the Latin American Regional Board, International Society of Nephrology. He is a member of the Steering Committee of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (AstraZeneca), the Study of Diabetic Nephropathy with Atrasentan (SONAR) (Abbvie), A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting (FINE-REAL) (Bayer), and CKD-ASI (Boehringer). He has received research grants from AstraZeneca, GlaxoSmithKline, Roche, Boehringer, and Novo Nordisk; and has received honoraria as a speaker from AstraZeneca, Bayer, Boehringer Ingelheim, and Amgen. All the other authors declared no competing interests.
Acknowledgments
The authors are grateful for the thoughtful input provided by members of the Advocacy Working Group and the Patient Liaison Advisory Group of the International Society of Nephrology: Elliot Tannor, Marcello Tonelli, Boris Bikbov, Maria Carlota Gonzalez, Vivekanand Jha, and Viviane Calice-Silva.
Medication/technology | Example | Reason | On the WHO model list of essential medicines |
---|---|---|---|
ACE inhibitor | Enalapril, lisinopril | Delays CKD progression, benefits cardiovascular disease and stroke | Yes |
Angiotensin receptor blocker | Losartan, telmisartan | Delays CKD progression, cardiovascular disease, and stroke | Yes |
Calcium channel blocker | Amlodipine, verapamil | Blood pressure control | Yes |
Loop diuretics | Furosemide, torsemide | Good when GFR is low, good for heart failure | Yes |
Thiazide diuretics | Hydrochlorothiazide, metolazone, indapamide | Good for blood pressure, especially in the Black population | Yes |
SGLT2 inhibitor | Empagliflozin, canagliflozin, dapagliflozin | Diabetes control, delays CKD progression, cardiovascular disease, and death | Yes |
GLP1 agonist | Semaglutide | Diabetes control, weight loss | No |
Mineralocorticoid inhibitor | Spironolactone, finerenone | Delays CKD progression, reduces heart failure risk | Yes/no |
Caution: risk of hyperkalemia in patients with kidney disease | |||
β-Blocker | Bisoprolol | Prevention and treatment of ischemic heart disease | Yes |
Statins | Simvastatin | Prevention of CAD in patients with CKD, transplant | Yes |
Aspirin | Secondary prevention of MI in patients with CKD, transplant | Yes | |
Fixed-dose combinations (polypill)a | Aspirin + atorvastatin + ramipril | Simultaneous management of CKD and cardiovascular disease and risk factors where indicateda | Yes |
Aspirin + simvastatin + ramipril + atenolol + hydrochlorthiazide | Yes | ||
Aspirin + perindopril + amlodipine | Yes | ||
Oral hypoglycemic medication | Gliclazide, metformin, SGLT2 inhibitors | DM management | Yes |
Caution with dosing and glomerular filtration rate | |||
Insulin | Long and short acting | DM management | Yes |
Valerie A. Luyckx
https://orcid.org/0000-0001-7066-8135
Katherine R. Tuttle
https://orcid.org/0000-0002-2235-0103
Dina Abdellatif
https://orcid.org/0000-0001-5398-3387
Ricardo Correa-Rotter
https://orcid.org/0000-0003-0100-8285
Winston W.S. Fung
https://orcid.org/0000-0001-7676-7628
Agnès Haris
https://orcid.org/0000-0001-8562-7977
Li-Li Hsiao
https://orcid.org/0000-0003-0830-3391
Makram Khalife
https://orcid.org/0000-0002-0541-8110
Latha A. Kumaraswami
https://orcid.org/0000-0003-2462-4726
Fiona Loud
https://orcid.org/0000-0001-7706-5396
Vasundhara Raghavan
https://orcid.org/0009-0008-5270-5762
Stefanos Roumeliotis
https://orcid.org/0000-0002-9423-649X
Ifeoma Ulasi
https://orcid.org/0000-0001-7783-3025
Bill Wang
https://orcid.org/0009-0008-6395-2240
Siu-Fai Lui
https://orcid.org/0000-0003-0800-8982
Vassilios Liakopoulos
https://orcid.org/0000-0002-7564-2724
Alessandro Balducci
https://orcid.org/0000-0002-7432-1494